Foundayo

Foundayo (Orforglipron) 14.5mg Tablets 1 x 30 are indicated for:

Weight management

Foundayo is indicated as an adjunct to a reduced-calorie diet and increased physical activity for weight management, including weight loss and weight maintenance, in adults with an initial Body Mass Index (BMI) of
 • ≥30 kg/m2 (obesity), or
 • ≥27 kg/m2 to < 30 kg/m2 (overweight) in the presence of at least one weight-related comorbidity e.g. prediabetes or type 2 diabetes mellitus, hypertension, dyslipidaemia, obstructive sleep apnoea, or cardiovascular disease.

Type 2 diabetes mellitus

Foundayo is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus to improve glycaemic control as an adjunct to diet and exercise:
 • as monotherapy, or
 • in combination with other medicinal products for the treatment of diabetes.

This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.

Available on request.

Available on request.